Optiver Holding
NBSE

Optiver Holding’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Optiver Holding’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-161
Closed -$12K – 910
2021
Q4 		$12K Hold
161
– – ﹤0.01% 682
2021
Q3 		$12K Hold
161
– – ﹤0.01% 550
2021
Q2 		$15K Buy
+161
New +$17.8K ﹤0.01% 407

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Optiver Holding's NBSE Position: Q1 2022 in Review

Optiver Holding sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2022, closing a stake of 161 shares — an estimated $12K sold.

Optiver Holding first reported a position in NBSE in Q2 2021 and held it in 3 quarters. The position peaked at $15K in Q2 2021. 45 funds tracked by Wall St. Rank hold NBSE as of Q1 2022.

  • Optiver Holding reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Optiver Holding sold 161 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $12K.
  • Optiver Holding first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Optiver Holding's NeuBase Therapeutics, Inc. Common Stock position peaked at $15K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Optiver Holding's 13F filing for Q1 2022, filed 16 May 2022.